Atlas Trials

A Study To Determine The Effect Of Ocrelizumab On Leptomeningeal Inflammation In Multiple Sclerosis

Clinical trial NCT05208840 · WITHDRAWN

Trial details

NCT number
NCT05208840
Sponsor
Hoffmann-La Roche
Status
WITHDRAWN
Phase
Phase 4
Study type
INTERVENTIONAL
Multiple Sclerosis
Start date
2023-09-15
Primary completion
2025-01-31
Enrollment
0

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.